Company records / immunovec.com

ImmunoVec

ImmunoVec (immunovec.com): 3 changes recorded in its website history since February 2021. Homepage last checked 6 November 2026.

Recorded changes

Newest observations first. Each interval bounds when the website changed; it is not an exact event date.

HeadlineBetween 22 January 2026 and 6 November 2026
BeforeAt ImmunoVec, we develop in vivo therapies to precisely engineer any targeted cell type within the human body.
AfterImmunoVec is pioneering the next generation of precise, durable in vivo medicines for cancer and autoimmune disease
Observed on the company’s website; business claims are not independently verified.
earlier archived page current websiteHistorical capture not publicly availableLink to observation
HiringBetween 17 July 2025 and 22 January 2026
Added a careers page.
Observed on the company’s website; business claims are not independently verified.
earlier archived page later archived page Link to observation
HeadlineBetween 17 July 2025 and 22 January 2026
BeforeGene Therapy for Hematopoietic Diseases
AfterAt ImmunoVec, we develop in vivo therapies to precisely engineer any targeted cell type within the human body.
Observed on the company’s website; business claims are not independently verified.
earlier archived page later archived page Link to observation

First recorded website

Observed 27 February 2021

Our earliest capture with readable facts. This is our first observation, not when the company introduced these things. These website claims are not independently verified.

How it described itself

Gene Therapy for Hematopoietic Diseases

archived page Link to first observation

All facts above belong to this capture. Unlisted fields mean we have no readable observation, not that they were absent.

How it describes itself

Similar headlines are grouped together. The quote shown is from the last capture in each group, not necessarily the exact wording throughout that period.

Seen November 2026 · 1 capture · latest observed messagingImmunoVec is pioneering the next generation of precise, durable in vivo medicines for cancer and autoimmune disease
At ImmunoVec, we develop in vivo therapies to precisely engineer any targeted cell type within the human body.
This wording observed 6 November 2026.
current websiteHistorical capture not publicly available
Seen January 2026 · 1 captureAt ImmunoVec, we develop in vivo therapies to precisely engineer any targeted cell type within the human body.
At ImmunoVec, we develop in vivo therapies to precisely engineer any targeted cell type within the human body.
This wording observed 22 January 2026.
archived page
February 2021 – July 2025 · 9 capturesGene Therapy for Hematopoietic Diseases
This wording observed 17 July 2025.
archived page
Inspect 9 captures in this group
- 27 February 2021 · Gene Therapy for Hematopoietic Diseases archived page
- 31 July 2021 · Gene Therapy for Hematopoietic Diseases archived page
- 29 January 2022 · Gene Therapy for Hematopoietic Diseases archived page
- 3 July 2022 · Gene Therapy for Hematopoietic Diseases archived page
- 1 February 2023 · Gene Therapy for Hematopoietic Diseases archived page
- 22 June 2024 · Gene Therapy for Hematopoietic Diseases archived page
- 24 July 2024 · Gene Therapy for Hematopoietic Diseases archived page
- 7 February 2025 · Gene Therapy for Hematopoietic Diseases archived page
- 17 July 2025 · Gene Therapy for Hematopoietic Diseases archived page

Summary of the record · AI-written

Written by an AI model on 7 November 2026 from the dated observations above; this is not the date the changes happened; each point links to the changes it rests on.

ImmunoVec updates positioning on in vivo medicines and adds careers page

ImmunoVec has revised its homepage messaging twice and added a careers page. The latest homepage wording emphasizes precise, durable in vivo medicines for cancer and autoimmune disease.

Between July 2025 and January 2026, ImmunoVec changed its homepage headline from “Gene Therapy for Hematopoietic Diseases” to a broader description of developing in vivo therapies to engineer targeted cell types in the human body. [1]
Between July 2025 and January 2026, ImmunoVec added a careers page to its website. [2]
Between January 2026 and November 2026, ImmunoVec changed its homepage headline to state that it is pioneering precise, durable in vivo medicines for cancer and autoimmune disease. [3]
Reading: The sequence of homepage headline changes between July 2025 and November 2026 suggests ImmunoVec may be narrowing its public focus from hematopoietic diseases to in vivo medicines for cancer and autoimmune disease. [1][3]

Cite this record

StartupHistory, “ImmunoVec” company record, https://startuphistory.org/c/immunovec.com

Machine-readable: /c/immunovec.com.json. How changes are found: method.